Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide
Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide
复制标题
DOI：
10.3324/haematol.2013.083972
复制
发表时间：
2013-11-01
期刊：
影响因子：
10.1
通讯作者：
Platzbecker, Uwe
中科院分区：
文献类型：
--
作者：
Ferrer, Ruben A.;Wobus, Manja;Platzbecker, Uwe
骨髓微环境在骨髓增生异常综合征中的作用存在争议。因此，我们分析了在来那度胺存在或不存在的情况下，骨髓增生异常综合征患者的原始间充质基质细胞的功能特性。与健康对照组相比，克隆性和生长在所有疾病阶段都有所减少。此外，还检测到分化缺陷以及黏附分子和细胞表面分子(如CD166、CD29、CD146)的特异性表达。有趣的是，患者细胞培养上清液中基质衍生因子1-α的水平几乎低2倍(P
The contribution of the bone marrow microenvironment in myelodysplastic syndrome is controversial. We therefore analyzed the functional properties of primary mesenchymal stromal cells from patients with myelodysplastic syndrome in the presence or absence of lenalidomide. Compared to healthy controls, clonality and growth were reduced across all disease stages. Furthermore, differentiation defects and particular expression of adhesion and cell surface molecules (e. g. CD166, CD29, CD146) were detected. Interestingly, the levels of stromal derived factor 1-alpha in patients' cells culture supernatants were almost 2-fold lower (P